Pfizer Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Company News
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
3 Things You Need to Know If You Buy Pfizer Stock Today
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
Should You Buy Pfizer Stock Below $30?
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't
Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC's ‘Final Trades'
Archer Investment Corp Acquires Shares of 73,546 Pfizer Inc. $PFE
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
US FDA approves updated COVID vaccines for 2026-27 season
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Wall Street Is Sleeping on These 3 Ultra-High-Yield Dividend Stocks
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
The Most Concerning Thing About Pfizer's Dividend Isn't What You Think